Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· April 13, 2026

Dollar firms on safe-haven demand amid escalating U.S.-Iran tensions: Currency Recap

View original at seekingalpha.com
Dollar firms on safe-haven demand amid escalating U.S.-Iran tensions: Currency Recap ardasavasciogullari The U.S. dollar edged up on Monday, as investors turned cautious following renewed geopolitical tensions and a shift back toward safe-haven demand after the collapse of U.S.-Iran peace talks…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • U.S. recession odds fade as economic data keep beating expectations

    60% confidence
  • Commodities to lead 'anything but bonds' trade through 2020s

    60% confidence
  • The dollar's rebound was supported by shifting expectations around global interest rate outlook, as rising energy prices and persistent inflation pressures reduced likelihood of near-term policy easing by major central banks

    60% confidence
  • The Japanese yen weakened even as geopolitical tensions escalated, suggesting limited safe-haven demand amid broader dollar strength

    60% confidence
  • Risk aversion intensified toward the latter part of the week as diplomatic efforts faltered and tensions escalated, including renewed threats to key energy shipping routes such as the Strait of Hormuz

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com